{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:07:32Z","timestamp":1784012852676,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Central venous access devices (CVADs) are commonly inserted in paediatric patients requiring cancer treatment and supportive care. However, these devices carry a high risk of complications such as central line-associated bloodstream infections (CLABSI), venous thromboembolism (VTE), and occlusion, and are associated with significant management costs. This study aimed to determine the average cost of each CVAD-associated complication type, per complication event, and investigate which elements are the key cost drivers of these estimates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This Australian prospective observational cohort study, embedded within a randomised controlled trial, acquired data from hospital purchasing departments, the Medicare Benefits Schedule Book, the National Hospital Cost Data Collection (NHCDC) Public Sector 2022\u20132023 Report, and local (state-based) enterprise bargaining agreements. Price per resource unit was multiplied by associated resource use and summed across all resources to estimate the mean complication cost per event. An average cost per complication event for each complication type was then determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In a sample of 310 paediatric oncology patients, 101 unique patients experienced 275 CVAD-associated complication events. Of these events, estimated per-event direct costs for CVAD-associated complications were as follows: occlusion (A$2712 (95% CI $1198\u2013$4225)), CVAD-associated venous thromboembolism (A$17,510 (95% CI $5840\u2013$29,181)), confirmed CLABSI (A$38,995 (95% CI $22,394\u2013$55,596)), and suspected CLABSI (A$16,030 (95% CI $12,971\u2013$19,090)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CVAD-associated complications remain a palpable cost in paediatric cancer care, with CLABSI carrying the highest cost burden. Therefore, investing in preventative care is encouraged to minimise the burden of complication costs to the healthcare system, and reduce the physical and emotional burden on patients and their families. With admission costs comprising a high percentage of complication-associated costs, efficient and effective evidence-based care must be delivered to ensure a shorter length of stay, simultaneously improving the patient experience.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-10942-1","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:21:31Z","timestamp":1782962491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Central venous access device\u2013associated complication costs in paediatric cancer care"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2577-8631","authenticated-orcid":false,"given":"Elouise R.","family":"Comber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Royle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Ullman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Keogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Eisenstat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Byrnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"10942_CR1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3389\/fped.2019.00260","volume":"7","author":"O Beck","year":"2019","unstructured":"Beck O, Muensterer O, Hofmann S, Rossmann H, Poplawski A, Faber J, G\u00f6deke J (2019) Central venous access devices (CVAD) in pediatric oncology patients-a single-center retrospective study over more than 9 years. Front Pediatr 7:260","journal-title":"Front Pediatr"},{"key":"10942_CR2","first-page":"1","volume":"0","author":"S deSouza","year":"2025","unstructured":"deSouza S, Takashima MD, Hyun A, Gibson V, Silva TL, Rocha PK, Vetcho S, Wen SCH, Ullman AJ (2025) Complications in central venous access devices in paediatric cancer care: a global cross-sectional survey. Eur J Haematol 0:1\u201311","journal-title":"Eur J Haematol"},{"key":"10942_CR3","volume":"32","author":"JL Nunn","year":"2024","unstructured":"Nunn JL, Takashima MD, Wray-Jones EM, Soosay Raj TA, Hanna DMT, Ullman AJ (2024) Central venous access device adverse events in pediatric patients with cancer: a systematic review and meta-analysis. Support Care Cancer 32:662","journal-title":"Support Care Cancer"},{"key":"10942_CR4","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1086\/673464","volume":"34","author":"AC Blanchard","year":"2013","unstructured":"Blanchard AC, Fortin E, Rocher I, Moore DL, Frenette C, Tremblay C, Quach C (2013) Central line-associated bloodstream infection in neonatal intensive care units. Infect Control Hosp Epidemiol 34:1167\u20131173","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10942_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/wvn.12574","volume":"19","author":"S Belloni","year":"2022","unstructured":"Belloni S, Caruso R, Cattani D, Mandelli G, Donizetti D, Mazzoleni B, Tedeschi M (2022) Occurrence rate and risk factors for long-term central line-associated bloodstream infections in patients with cancer: a systematic review. Worldviews Evid Based Nurs 19:100\u2013111","journal-title":"Worldviews Evid Based Nurs"},{"key":"10942_CR6","volume":"15","author":"KM Alshahrani","year":"2023","unstructured":"Alshahrani KM, Alhuwaishel AZ, Alangari NM, Asiri MA, Al-Shahrani NA, Alasmari AA, Alzahrani OJ, Ayedh AY, Qitmah MM (2023) Clinical impacts and risk factors for central line-associated bloodstream infection: a systematic review. Cureus J Med Sci 15:e40954","journal-title":"Cureus J Med Sci"},{"key":"10942_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1182\/asheducation-2014.1.306","volume":"2014","author":"W Geerts","year":"2014","unstructured":"Geerts W (2014) Central venous catheter\u2013related thrombosis. Hematology 2014:306\u2013311","journal-title":"Hematology"},{"key":"10942_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10100380","volume":"10","author":"NB Abdol Razak","year":"2018","unstructured":"Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P (2018) Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel) 10:380","journal-title":"Cancers (Basel)"},{"key":"10942_CR9","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41390-022-01977-1","volume":"92","author":"AJ Ullman","year":"2022","unstructured":"Ullman AJ, Gibson V, Takashima MD, Kleidon TM, Schults J, Saiyed M, Cattanach P, Paterson R, Cooke M, Rickard CM, Byrnes J, Chopra V (2022) Pediatric central venous access devices: practice, performance, and costs. Pediatr Res 92:1381\u20131390","journal-title":"Pediatr Res"},{"key":"10942_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jhin.2025.11.009","volume":"169","author":"ER Comber","year":"2026","unstructured":"Comber ER, Ullman A, Hall S, Takashima M, Nguyen L, Keogh S, Byrnes J (2026) Central venous access device-associated complication costs in paediatrics: a systematic review. J Hosp Infect 169:59\u201367","journal-title":"J Hosp Infect"},{"key":"10942_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-085637","volume":"14","author":"A Ullman","year":"2024","unstructured":"Ullman A, Takashima M, Gibson V, Comber E, Borello E, Bradford N, Byrnes J, Cole R, Eisenstat D, Henson N, Howard P, Irwin A, Keogh S, Kleidon T, Martin M, McCleary K, McLean J, Moloney S, Monagle P, Moore A, Newall F, Noyes M, Rowan G, St John A, Wood A, Wolf J, Ware R (2024) Preventing adverse events during paediatric cancer treatment: protocol for a multi-site hybrid randomised controlled trial of catheter lock solutions (the CLOCK trial). BMJ Open 14:e085637","journal-title":"BMJ Open"},{"key":"10942_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1049","volume":"346","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E (2013) Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ 346:e067975","journal-title":"BMJ"},{"key":"10942_CR13","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/cncr.20910","volume":"103","author":"E Steliarova-Foucher","year":"2005","unstructured":"Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P (2005) International classification of childhood cancer, third edition. Cancer 103:1457\u20131467","journal-title":"Cancer"},{"key":"10942_CR14","volume-title":"National healthcare safety network (NHSN) patient safety component manual: bloodstream infection event","author":"Centers for Disease Control Prevention","year":"2020","unstructured":"Centers for Disease Control Prevention (2020) National healthcare safety network (NHSN) patient safety component manual: bloodstream infection event. US Government, Atlanta"},{"key":"10942_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-017-3606-9","volume":"17","author":"AJ Ullman","year":"2017","unstructured":"Ullman AJ, Kleidon T, Gibson V, McBride CA, Mihala G, Cooke M, Rickard CM (2017) Innovative dressing and securement of tunneled central venous access devices in pediatrics: a pilot randomized controlled trial. BMC Cancer 17:1\u201312","journal-title":"BMC Cancer"},{"key":"10942_CR16","first-page":"755","volume":"24","author":"GA Goossens","year":"2016","unstructured":"Goossens GA, De Waele Y, J\u00e9r\u00f4me M, Fieuws S, Janssens C, Stas M, Moons P (2016) Diagnostic accuracy of the Catheter Injection and Aspiration (CINAS) classification for assessing the function of totally implantable venous access devices. Support Care Cancer 24:755\u2013761","journal-title":"Support Care Cancer"},{"key":"10942_CR17","unstructured":"Independent Health and Aged Care Pricing Authority (2023) National Hospital Cost Data Collection (NHCDC) Public Sector 2022\u201323. https:\/\/www.ihacpa.gov.au\/resources\/national-hospital-cost-data-collection-nhcdc-public-sector-2022-23. Accessed 30 Nov 2025"},{"key":"10942_CR18","unstructured":"Australian Government Department of Health and Aged Care (2020) Medicare benefits schedule. https:\/\/www.mbsonline.gov.au\/internet\/mbsonline\/publishing.nsf\/Content\/Downloads-202001. Accessed 30 Nov 2025"},{"key":"10942_CR19","unstructured":"Queensland Health (2025) Wage rates \u2013 medical stream. https:\/\/www.health.qld.gov.au\/hrpolicies\/wage-rates\/medical. Accessed 10 Dec 2025"},{"key":"10942_CR20","unstructured":"Queensland Health (2025) Wage rates - nursing stream. Wage rates - Nursing Stream. https:\/\/www.health.qld.gov.au\/hrpolicies\/wage-rates\/nursing. Accessed 10 Dec 2025"},{"key":"10942_CR21","unstructured":"Reserve Bank of Australia (2026) Inflation calculator. https:\/\/www.rba.gov.au\/calculator\/annualDecimal.html. Accessed 24 Feb 2025"},{"key":"10942_CR22","volume":"2025","author":"JL Nunn","year":"2025","unstructured":"Nunn JL, Takashima MD, Wray-Jones EM, Soosay Raj TA, Hanna DM, Ullman AJ (2025) Identifying risk factors for central venous access device complications in pediatric patients with cancer: a scoping review. Eur J Cancer Care 2025:e9956694","journal-title":"Eur J Cancer Care"},{"key":"10942_CR23","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.ajic.2014.07.025","volume":"42","author":"MZ Wilson","year":"2014","unstructured":"Wilson MZ, Rafferty C, Deeter D, Comito MA, Hollenbeak CS (2014) Attributable costs of central line-associated bloodstream infections in a pediatric hematology\/oncology population. Am J Infect Control 42:1157\u20131160","journal-title":"Am J Infect Control"},{"key":"10942_CR24","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/pbc.26194","volume":"64","author":"CI Wong Quiles","year":"2017","unstructured":"Wong Quiles CI, Gottsch S, Thakrar U, Fraile B, Billett AL (2017) Health care institutional charges associated with ambulatory bloodstream infections in pediatric oncology and stem cell transplant patients. Pediatr Blood Cancer 64:324\u2013329","journal-title":"Pediatr Blood Cancer"},{"key":"10942_CR25","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/wvn.12548","volume":"18","author":"K Chovanec","year":"2021","unstructured":"Chovanec K, Arsene C, Gomez C, Brixey M, Tolles D, Galliers JW, Kopaniasz R, Bobash T, Goodwin L (2021) Association of CLABSI with hospital length of stay, readmission rates, and mortality: a retrospective review. Worldviews Evid Based Nurs 18:332\u2013338","journal-title":"Worldviews Evid Based Nurs"},{"key":"10942_CR26","volume":"12","author":"NH Alotaibi","year":"2020","unstructured":"Alotaibi NH, Barri A, Elahi MA (2020) Length of stay in patients with central line-associated bloodstream infection at a tertiary hospital in the Kingdom of Saudi Arabia. Cureus 12:e10820","journal-title":"Cureus"},{"key":"10942_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.mjafi.2013.08.001","volume":"70","author":"A Kumar","year":"2014","unstructured":"Kumar A, Sharma RM, Jaideep CN, Hazra N (2014) Diagnosis of central venous catheter-related bloodstream infection without catheter removal: a prospective observational study. Med J Armed Forces India 70:17\u201321","journal-title":"Med J Armed Forces India"},{"key":"10942_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2023.104620","volume":"149","author":"H Xu","year":"2024","unstructured":"Xu H, Hyun A, Mihala G, Rickard CM, Cooke ML, Lin F, Mitchell M, Ullman AJ (2024) The effectiveness of dressings and securement devices to prevent central venous catheter-associated complications: a systematic review and meta-analysis. Int J Nurs Stud 149:104620","journal-title":"Int J Nurs Stud"},{"key":"10942_CR29","doi-asserted-by":"crossref","unstructured":"Ornowska M, Wittmann J, Blitz S, Wong H, Vazquez-Grande G, Mitra AR, Jang W, Wood G, Ovakim D, Forrest D, Rohrs E, Reynolds S (2026) 4% tetrasodium EDTA to prevent central venous access device\u2013associated complications: a randomized clinical trial. JAMA\u00a0335(24):2126\u20132134","DOI":"10.1001\/jama.2026.6025"},{"key":"10942_CR30","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-063264","author":"M Takashima","year":"2024","unstructured":"Takashima M, Ezure Y, Furuya-Kanamori L, Wolf J, Dufficy M, Gibson V, Clark J, Ullman A (2024) Pediatric central venous access device lock solutions: a network meta-analysis. Pediatrics. https:\/\/doi.org\/10.1542\/peds.2023-063264","journal-title":"Pediatrics"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10942-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10942-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10942-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:45:43Z","timestamp":1784011543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10942-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10942"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10942-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Children\u2019s Health Queensland Hospital and Health Service Human Research Ethics Committee (HREC) (HREC\/22\/QCHQ\/81744) on 25 February 20222 and the University of Queensland HREC (2022\/HE000196) on 8 March 2022, with subsequent governance approval at all sites.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants (or their caregiver) included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"AJU discloses her employer (the University of Queensland) has received investigator-initiated research grants from product manufacturers (Solventum, Eloquest, Biolife) unrelated to the submitted work. SK reports monies received by her employer on her behalf from BD Medical for educational consultancies unrelated to this study. JB reports funding provided to his employer from NeoNav unrelated to this study. There are no other potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"718"}}